Concert, Merrimack, Vertex, & More
Summary
In fact, as CEO Roger Tung told me last week, that IPO was almost dead on arrival when the company got some disastrous data on its kidney disease drug, CTP-499 while it was drafting its S-1.The news is the latest small step in Vertex’s plan to treat more and more subsets of the cystic fibrosis population by combining ivacaftor with other experimental drugs in its portfolio.—Cranbury, NJ-based Amicus Therapeutics (NASDAQ: FOLD) got a stock bump this week after it said that its oral Fabry disease drug, migalastat Hcl, posted some positive results in a Phase 3 trial.Civitas’ drug-device combo is being developed as an adjunct therapy to levodopa pills, which are used by most Parkinson’s patients to manage symptoms, but tend to produce erratic levels of drug in the bloodstream.—Lexington, MA-based Agenus (NASDAQ: AGEN) this week parlayed its February acquisition of antibody discovery shop 4-Antibody into a collaboration deal with Merck to unearth new “checkpoint inhibitors” to treat cancer.
Classifications
AskAI Classifications
LabelsLinked Companies
